Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$5.43
-6.3%		$4.94
$1.90
▼
$10.59
$7.92M3.05625,014 shs1,472 shs
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
$10.87
+2.6%		$13.26
$2.88
▼
$18.20
$22.65M-1.562,929 shs79,982 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+9.7%		$0.01
$0.00
▼
$0.03
$106K1.86102,703 shs11,003 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.71
+4.3%		$1.54
$0.13
▼
$1.04
$32.93M1.581.05 million shs84,345 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-0.52%+14.20%+14.20%-19.02%-24.81%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
-5.87%-24.57%-23.26%-25.11%+61.93%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
+3.33%-22.50%-38.00%-55.07%-90.43%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00%+9.33%+10.07%+16.31%-66.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$5.43
-6.3%		$4.94
$1.90
▼
$10.59
$7.92M3.05625,014 shs1,472 shs
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
$10.87
+2.6%		$13.26
$2.88
▼
$18.20
$22.65M-1.562,929 shs79,982 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+9.7%		$0.01
$0.00
▼
$0.03
$106K1.86102,703 shs11,003 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.71
+4.3%		$1.54
$0.13
▼
$1.04
$32.93M1.581.05 million shs84,345 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-0.52%+14.20%+14.20%-19.02%-24.81%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
-5.87%-24.57%-23.26%-25.11%+61.93%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
+3.33%-22.50%-38.00%-55.07%-90.43%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00%+9.33%+10.07%+16.31%-66.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.00
Hold$20.00268.66% Upside
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
1.00
SellN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00
N/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CNSP, PTPI, VIRI, and PLRZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/26/2026
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/11/2026
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/21/2026
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/4/2026
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$7.29 per shareN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/A$13.05 per shareN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.11M0.02N/AN/A$4.04 per share0.00
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$15.85M-$29.63N/AN/AN/AN/A-238.68%-166.30%8/17/2026 (Estimated)
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
-$3.34MN/AN/AN/AN/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$1.64N/AN/AN/AN/A-78.22%-23.50%N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/A

Latest CNSP, PTPI, VIRI, and PLRZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/17/2026Q2 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$0.24N/AN/AN/AN/AN/A
5/14/2026Q1 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$8.82-$7.30+$1.52-$7.30N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
0.89
0.89
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
29.03
29.03
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
1.58
0.85
0.74
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
0.01%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.25%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
51.46 million1.46 millionNot Optionable
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A2.08 millionN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
2031.16 million9.93 millionNot Optionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionNo Data

Recent News About These Companies

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply
June 13, 2025  |  thelancet.comT
Dogwood Therapeutics Inc (DWTX)
March 16, 2025  |  investing.comhttps://www.investing.com/equities/virios-therapeutics-llc-news/6
Dogwood prices 578,950 shares at $8.26 in registered direct offering
March 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-prices-578-950-shares-at-8-26-in-registered-direct-offering-1034474303
Dogwood announces conversion of existing $19.5M in debt to equity
March 12, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-announces-conversion-of-existing-19-5m-in-debt-to-equity-1034469161
DWTX Stock trading resumes
February 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dwtx-stock-trading-resumes-1034343398
Dogwood Therapeutics, Inc. (DWTX)
February 2, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/DWTX/news/
DWTX Stock trading halted, volatility trading pause
January 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dwtx-stock-trading-halted-volatility-trading-pause-1034273379
DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth
January 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/dwtx-stock-hits-52-week-high-at-1574-amidst-strong-yearly-growth/ar-AA1xK7SQ
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
January 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-announces-first-patient-dosed-in-phase-2b-trial-on-halneuron-1034250966
Polluted communities hold their breath as companies struggle with California’s diesel truck ban
December 10, 2024  |  apnews.comA
Dogwood Therapeutics faces potential Nasdaq delisting
November 23, 2024  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/dogwood-therapeutics-faces-potential-nasdaq-delisting-93CH-3803100
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
November 18, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-says-low-dose-imc-2-treatment-reduces-long-covid-fatigue-1034031983
Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance
November 18, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-study-finds-imc-2-treatment-reduces-long-covid-related-fatigue-sleep-disturbance-1034030784
Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary
November 16, 2024  |  benzinga.comhttps://www.benzinga.com/quote/INO
DWTX: Phase 2 Long COVID Results Expected Soon
November 12, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/dwtx-phase-2-long-covid-results-expected-soon/ar-AA1tTHga
Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence
November 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-for-dogwood-therapeutics-strategic-initiatives-and-promising-pipeline-drive-analyst-confidence-1033984881
Dogwood Therapeutics Reports Q3 2024 Financial Results
November 9, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-therapeutics-reports-q3-2024-financial-results-1033980327
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
November 8, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/dogwood-therapeutics-announces-third-quarter-2024-financial-results-1033969465
Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 31, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-10/63674189-dogwood-therapeutics-inc-dogwood-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-399.htm
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 30, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/dogwood-therapeutics-regains-compliance-nasdaq-131500585.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$5.42 -0.37 (-6.30%)
As of 12:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Polyrizon stock logo

Polyrizon NASDAQ:PLRZ

$10.87 +0.28 (+2.62%)
As of 12:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Petros Pharmaceuticals stock logo

Petros Pharmaceuticals NASDAQ:PTPI

$0.0034 +0.00 (+9.68%)
As of 11:23 AM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$1.71 +0.07 (+4.27%)
As of 08/3/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas